Document:

EX-10.1

 Exhibit 10.1 

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS AGREEMENT (INDICATED BY “[***]”) BECAUSE TAYSHA GENE THERAPIES, INC. HAS
DETERMINED SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 OPTION AGREEMENT

 This Option Agreement (this “Agreement”) is dated as of October 21, 2022 (the “Effective
Date”) by and between Taysha Gene Therapies, Inc., with a place of business at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247 (“Taysha”) and Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) with its
principal place of business at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Astellas”). Taysha and Astellas may be referred to herein as a “Party” or, collectively, as “Parties”.

 RECITALS 

WHEREAS, Taysha is a gene therapy company that engages in the research, development and manufacturing of proprietary biopharmaceutical
and therapeutic products; 
 WHEREAS, in addition to other programs, Taysha has in development two proprietary programs, one for the
treatment of giant axonal neuropathy (“GAN”) and one for the treatment of Rett syndrome (“Rett”); 

WHEREAS, Astellas desires to obtain (1) two options from Taysha to exclusively license the rights to develop, manufacture,
commercialize and otherwise exploit Taysha products for the treatment of GAN and the treatment of Rett and (2) certain rights with respect to a Change of Control (as defined below) of Taysha, in each case ((1) and (2)), as set forth more
specifically herein; 
 WHEREAS, Taysha is willing to grant such options and rights pursuant to the terms set forth herein; and 

WHEREAS, the Parties are entering into the Securities Purchase Agreement (the “SPA”) concurrently herewith. 

NOW, THEREFORE, in consideration of the various promises and undertakings set forth herein, the sufficiency of which is hereby
acknowledged, the Parties agree as follows: 
 ARTICLE 1 

DEFINED TERMS 
 In addition
to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated below: 
  

	1.1	 “120 GAN Product Diligence Package” means the documents and materials furnished to Astellas or
its Affiliates in the electronic data room in connection with its or their diligence prior to the Effective Date with respect to the 120 GAN Product. 

  

	1.2	 “Affiliate” has the meaning provided in the SPA. 

 

	1.3	 “Business Day” means any day except Saturday, Sunday and any day that is a legal holiday or a
day on which banking institutions in Japan or the state of New York generally are authorized or required by law or other government actions to close. 

  

	1.4	 “Commercially Reasonable Efforts” means, with respect to the activities of Taysha with respect
to the research, development, manufacturing and commercialization of the 102 Rett Product, the carrying out of such activities in a sustained and diligent manner and using efforts and resources which are typically used in the biopharmaceutical
industry for companies of a comparable condition 

	 	
and size similarly situated in the same industry as Taysha in the research, development, manufacture and commercialization of products of comparable market potential to the 102 Rett Product.
Commercially Reasonable Efforts requires that Taysha, at a minimum, (a) assign responsibility for the applicable activities to qualified employees, (b) set goals and objectives for carrying out such activities, and (c) allocate
adequate resources designed to meet such goals and objectives. 

  

	1.5	 “Control” means, with respect to products, intellectual property, regulatory documentation,
data or information, that Taysha or any of its Affiliates (a) owns or has a license, sublicense or other right to such products, intellectual property, regulatory documentation, data or information and (b) has the ability to provide, grant
a license or sublicense to, or assign its right, title and interest in and to, such products, intellectual property, regulatory documentation, data or information as provided for in this Agreement or any subsequent license agreement as expressly
contemplated herein with respect to either Option, as applicable, without violating the terms of any other agreement with any third party from whom Taysha or its Affiliate acquired or licensed such, products, intellectual property, regulatory
documentation, data or information. Notwithstanding anything in this Agreement to the contrary, if Taysha undergoes a Change of Control, Taysha shall not be deemed to Control any products, intellectual property, regulatory documentation, data or
information that are owned or controlled by any acquiring third party, or such acquiring third party’s Affiliates (other than Affiliates of Taysha prior to such Change of Control), either prior to or following such transaction, and all such
products, intellectual property, regulatory documentation, data and information are expressly excluded from the Options granted herein and any license agreement to be entered into arising from the exercise of either Option; provided that the
foregoing shall not apply to any products, intellectual property, regulatory documentation, data or information which is (i) used by Taysha or any of its Affiliates, before or after the effective date of the Change of Control, in the research,
development, manufacture or commercialization of any GAN Product or any Rett Product; (ii) Controlled by Taysha or its Affiliates prior to the effective date of the Change of Control (including any modification, improvement or derivation
thereof); or (iii) without limitation to the foregoing, owned or controlled by such acquiring third party or its Affiliates as a result of a license or other grant of rights by Taysha or any of its Affiliates existing prior to the effective
date of the Change of Control. 

  

	1.6	 “FDA” means the United States Food and Drug Administration and any successor entity thereto.

  

	1.7	 “Female Pediatric Study” means the clinical trial of the 102 Rett Product in female subjects
under the age of eighteen (18) years old consisting of [***]. 

  

	1.8	 “GAN Product” means (a) the product known, as of the Effective Date, as TSHA-120 (the “120 GAN Product”) and any backup products with respect thereto for use in the treatment of GAN; or (b) any other gene therapy product for use in the treatment of GAN
(i) Controlled by Taysha or any of its Affiliates or (ii) with respect to which Taysha or any of its Affiliates Controls intellectual property rights covering the Exploitation thereof. 

 

	1.9	 “Rett Data Package” means, with respect to the Rett Products, as applicable, an information
package that includes the following: (a) all material data (including, for clarity, non-clinical data, clinical data and chemistry, manufacturing and controls data) and analyses thereof generated by or on
behalf of Taysha or its Affiliates with respect to such products; (b) a detailed summary of such data and analyses, including with respect to safety and efficacy of such products; (c) a schedule identifying all third party intellectual
property rights then-known to Taysha or any of its Affiliates that may be required to develop, manufacture or commercialize such products; (d) any written notices received from a third party alleging that Exploitation of such products may
infringe or 

  
 2 

	 	
misappropriate the intellectual property rights of such third party; (e) copies of any then-existing agreements between Taysha or any of its Affiliates and any third party for the in-license or acquisition of any intellectual property rights for use in the Exploitation of such products; (f) any then-existing protocols and designs (including statistical analysis plans) for anticipated
clinical studies with respect to such products; (g) a summary of then-anticipated development activities for such products; (h) any market analyses conducted by Taysha or any of its Affiliates with respect to such products; (i) any
regulatory documentation Controlled by Taysha or any of its Affiliates with respect to such products; (j) a schedule of all then-existing patents and patent applications Controlled by Taysha or any of its Affiliates that claim or cover such
products, any component thereof or the Exploitation of any of the foregoing; and (k) a list of third party contract manufacturers used with respect to such products and copies of any then-existing agreements with such third parties with respect
to such products, in each case ((a)-(k)), anywhere in the world. 

  

	1.10	 “Rett Development Plan” means the detailed written plan for any research, development,
manufacturing and commercialization activities related to the 102 Rett Product during the Rett Option Period and any Option Negotiation Period with respect to the Rett Option, which plan shall (a) identify the research, development,
manufacturing and commercialization objectives, the timelines to achieve such objectives and the activities to be conducted in support of such objectives, and (b) contain a detailed budget identifying the costs and expenses associated with such
research, development, manufacturing and commercialization activities (the “Rett Budget”). 

  

	1.11	 “Rett Product” means (a) the product known, as of the Effective Date, as TSHA-102 (the “102 Rett Product”) and any backup products with respect thereto for use in the treatment of Rett; or (b) any other gene therapy product for use in the treatment of Rett
(i) Controlled by Taysha or any of its Affiliates or (ii) with respect to which Taysha or any of its Affiliates Controls intellectual property rights covering the Exploitation thereof. 

 

	1.12	 “Safety and Efficacy Readout Data” means the report containing all safety and efficacy data
from the six (6)-month initial observation period from subjects treated in cohort 1 of the Female Pediatric Study. 

  

	1.13	 “Type B Meeting” means the end of phase 2 meeting between Taysha and the FDA in response to
Taysha’s meeting request sent to the FDA on September 19, 2022 for the 120 GAN Product. 

  

	1.14	 “Type B Meeting Information” means (a) the minutes from the Type B Meeting, (b) all
written feedback from the FDA with respect to the Type B Meeting and (c) all briefing documents sent by Taysha to the FDA with respect to the Type B Meeting. 

 

	1.15	 “Upstream In-License” means any agreement with a third
party pursuant to which Taysha or any of its Affiliates have in-licensed material intellectual rights necessary or reasonably useful for the Exploitation of the GAN Products or the Rett Products, including
(a) any such agreement requiring future milestone, royalty or other payments with respect to a GAN Product or Rett Product, (b) the HHF License (as defined in the GAN Key Terms), (c) the Abeona Rett License (as defined in the Rett Key
Terms) and (d) the Research, Collaboration & License Agreement dated as of November 19, 2019 by and between The Board of Reagents of the University of Texas System and Taysha, as amended on April 2, 2020 (the “UT
License”). 

  
 3 

 ARTICLE 2 

CONSIDERATION 
  

	2.1	 Upfront Payment. As partial consideration for the rights granted to Astellas hereunder, Astellas will
pay to Taysha a one (1)-time payment in the amount of twenty million United States dollars ($20,000,000) (the “Upfront Payment”) within thirty (30) days after receipt of an invoice for the Upfront Payment, which invoice shall
be delivered to Astellas on or after the Effective Date and shall include wire transfer instructions for Astellas to pay such amount.  

  

	2.2	 Right of Offset. Astellas or any of its Affiliates shall have the right, in its or their discretion and
upon written notice to Taysha, to offset the amount of the Upfront Payment (in whole or in part, until the full amount of the Upfront Payment has been offset) against (a) any payment(s) owed to Taysha or any of its Affiliates (or to any third
party on behalf of Taysha) under or in connection with any license agreement entered into with respect to any GAN Product or Rett Product, including, any upfront payment, milestone payment or royalties owed to Taysha or any of its Affiliates (or to
any third party on behalf of Taysha) under or in connection with any such license agreement or (b) any amount owed to Taysha or any of its Affiliates in connection with a Change of Control transaction with Astellas or any of its Affiliates.

 ARTICLE 3 

OPTION 
  

	3.1	 GAN Option Grant to Astellas. In partial consideration for the Parties entering into the SPA and the
Upfront Payment, Taysha hereby grants to Astellas, during the GAN Option Period, an exclusive option to obtain an exclusive, worldwide, royalty- and milestone-bearing right and license (a) to research, develop, make, have made, use, sell, offer
for sale, have sold, import, export and otherwise exploit (collectively, “Exploit”) any GAN Product and (b) under any intellectual property rights Controlled by Taysha or any of its Affiliates with respect to such Exploitation
(the “GAN Option”). 

  

	 	3.1.1	 Exercise of the GAN Option. Astellas may exercise the GAN Option by providing written notice to Taysha
of its GAN Option exercise (the “GAN Exercise Notice”) at any time during the period commencing on the Effective Date and (subject to extension under Section 3.1.3 or the last sentence of this Section 3.1.1) ending at
[***] after the GAN Data Package Delivery Date (the “GAN Option Period”). Subject to any ongoing bona fide negotiations between the Parties pursuant to Article 4 (during which the GAN Option Period shall be tolled), in the event
that Astellas does not provide its written GAN Exercise Notice within the GAN Option Period to Taysha, such GAN Option shall expire. 

  

	 	3.1.2	 Updates and Meetings. During the GAN Option Period and any Option Negotiation Period with respect
to the GAN Option, within [***] Taysha shall (a) deliver to Astellas a written report containing a summary of all material research, development, manufacturing and commercialization activities conducted with respect to GAN Products during such
calendar month (if any); provided that if at any time during the GAN Option Period and any Option Negotiation Period with respect to the GAN Option, Taysha becomes aware of any new information related to the 120 GAN Product that is
reasonably likely to materially impact the development or commercialization of the 120 GAN Product, Taysha shall promptly provide such information to Astellas, but in any event in no more than [***] after Taysha becomes aware of such information;
and (b) promptly notify Astellas of any meeting with the FDA related to the 120 GAN Product and, [***]. During the GAN Option Period and any Option Negotiation Period with respect to the GAN Option, at Astellas’ reasonable written request,
Taysha shall promptly (i) meet with Astellas to discuss the contents of any such report and any activities with respect to any GAN Product; or (ii) deliver to Astellas any additional information reasonably requested by Astellas with
respect to any GAN Product; provided that such information is Controlled by Taysha or any of its Affiliates, including any data generated in any such research, development, manufacturing or commercialization activities. 

  
 4 

	 	3.1.3	 GAN Data Package. Without limiting Taysha’ obligations set forth in Section 3.1.2, Taysha
shall (a) from the Effective Date until expiration of the GAN Option Period (or any Option Negotiation Period with respect to the GAN Option), continue to provide Astellas access to the electronic data room containing the 120 GAN Product
Diligence Package and (b) within [***] after receipt of the Type B Meeting Information by Taysha or its Affiliate, provide Astellas with a true, complete and correct copy of such Type B Meeting Information (the 120 GAN Product Diligence Package
and the copy of the Type B Meeting Information, collectively, the “GAN Data Package”, and the date that Astellas receives the Type B Meeting Information, the “GAN Data Package Delivery Date”). If Astellas determines
that items are missing from the GAN Data Package, then, within [***] after Astellas’ request (which may be made via email) and provided that such information is Controlled by Taysha or any of its Affiliates, Taysha shall add such items
to the electronic data room [***]. 

  

	3.2	 Rett Option Grant to Astellas. In partial consideration for the Parties entering into the SPA and the
Upfront Payment, Taysha hereby grants to Astellas, during the Rett Option Period, an exclusive option to obtain an exclusive, worldwide, royalty- and milestone-bearing right and license (a) to Exploit any Rett Product and (b) under any
intellectual property rights Controlled by Taysha or any of its Affiliates with respect to such Exploitation (the “Rett Option”, together with the GAN Option, the “Options” and individually, each, an
“Option”). 

  

	 	3.2.1	 Rett Development Plan. The initial Rett Development Plan is attached as Exhibit A. Taysha shall
use Commercially Reasonable Efforts to complete all activities set forth in the Rett Development Plan, in accordance therewith (including the timelines set forth therein and the Rett Budget). Astellas’ prior written consent (which may be
provided by email) shall be required for any material deviation from the Rett Development Plan, including any material deviation from the Rett Budget; provided that Taysha shall promptly inform Astellas of any planned deviation from the Rett
Development Plan, including any planned deviation from the Rett Budget. 

  

	 	3.2.2	 Exercise of Rett Option. Astellas may exercise the Rett Option by providing written notice to
Taysha of its Rett Option exercise (the “Rett Exercise Notice”, together with the GAN Exercise Notice, each an “Exercise Notice”) at any time during the period commencing on the Effective Date and (subject to
extension under Section 3.2.4 or the last sentence of this Section 3.2.2) ending at [***] after the Rett Data Package Delivery Date (the “Rett Option Period”). Subject to any ongoing negotiations between the Parties
pursuant to Article 4 (during which the Rett Option Period shall be tolled), in the event that Astellas does not provide its written Rett Exercise Notice within the Rett Option Period to Taysha, such Rett Option shall expire. 

 

	 	3.2.3	 Updates and Meetings. During the Rett Option Period and any Option Negotiation Period with
respect to the Rett Option, [***] Taysha shall (a) deliver to Astellas a written report summarizing Taysha’s progress with respect to the Rett Development Plan and Rett Budget, which report shall include all material research, development,
manufacturing and commercialization activities conducted with respect to Rett Products during such calendar quarter, as well as the results of any clinical studies or material non-clinical studies;
provided that if at any time during the Rett Option Period and any Option Negotiation Period with respect to the Rett Option, Taysha becomes aware of any new information 

  
 5 

	 	
related to the 102 Rett Product that is reasonably likely to materially impact the development or commercialization of the 102 Rett Product, Taysha shall promptly provide such information to
Astellas[***] after Taysha becomes aware of such information; and (b) promptly notify Astellas of any meeting with the FDA related to the 102 Rett Product and, to the extent allowed by applicable law and unless otherwise not possible based on
the requested timing from the FDA[***]. During the Rett Option Period and any Option Negotiation Period with respect to the Rett Option, at Astellas’ reasonable written request, Taysha shall promptly (i) meet with Astellas to discuss the
contents of any such report and any activities with respect to any Rett Product; or (ii) deliver to Astellas any additional information reasonably requested by Astellas with respect to any Rett Product; provided that such information is
Controlled by Taysha or any of its Affiliates, including any data generated in any such research, development, manufacturing or commercialization activities. 

  

	 	3.2.4	 Rett Data Package. Without limiting Taysha’ obligations set forth in Section 3.2.3, within (a)
[***] after delivery to Astellas of the Safety and Efficacy Readout Data, which Taysha shall so deliver to Astellas [***] after such data becomes available or (b) [***] after Astellas’ written request, if such request is delivered to Taysha
prior to the delivery to Astellas of the complete Safety and Efficacy Readout Data, in each case, ((a) and (b)), Taysha shall grant Astellas access to an electronic data room containing the information then available comprising the Rett Data Package
(the date that Astellas receives such access, the “Rett Data Package Delivery Date”). If Astellas determines that items are missing from what has then been provided as the Rett Data Package, then, within [***] after Astellas’
request (which may be made via email), Taysha shall add such items to the electronic data room [***]. Following the Rett Data Package Delivery Date, Taysha shall promptly update the Rett Data Package during the remainder of the Rett Option Period,
and any Option Negotiation Period with respect to the Rett Option, to incorporate any new information that would have been included in the Rett Data Package if such new information had existed as of the Rett Data Package Delivery Date , which
updates shall be made [***] after generation or receipt of any such new information by Taysha or any of its Affiliates. 

  

	3.3	 Option Negotiation Period. For a period of [***] from the date that Taysha receives the applicable
Exercise Notice or such longer period as the Parties may mutually agree in writing (each, an “Option Negotiation Period”), the Parties shall negotiate in good faith the terms and conditions of an agreement for Astellas to obtain an
exclusive, worldwide, royalty- and milestone-bearing right and license to Exploit GAN Products or Rett Products, as applicable, which agreement shall be consistent with the terms and conditions (a) set forth in Exhibit B (the
“GAN Key Terms”), in the case of GAN Products or (b) set forth in Exhibit C (the “Rett Key Terms”), in the case of Rett Products. If the Parties are unable to enter into such an agreement by the end of
the [***] of the applicable Option Negotiation Period, then (i) Astellas shall have the right, during the remainder of such Option Negotiation Period, to refer such matter for resolution by baseball arbitration in accordance with Exhibit
D and (ii) if Astellas makes such referral, the Option Negotiation Period shall be deemed to continue until [***]. 

  

	3.4	 No Implied License. Each Party acknowledges that the rights granted in this Agreement are limited to the
scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the
other Party. All rights with respect to any know-how, patent or other intellectual property rights that are not specifically granted herein are reserved to the owner thereof. 

  
 6 

 ARTICLE 4 

CHANGE OF CONTROL 
  

	4.1	 Right of First Offer. During the Rett Option Period, Taysha will not (a) solicit or encourage any
inquiries, offers or proposals for, or that could reasonably be expected to lead to, a Change of Control, or (b) otherwise initiate a process for a potential Change of Control, in each case without first notifying Astellas in writing (a
“ROFO Notice”) and offering Astellas the opportunity to submit an offer or proposal to Taysha for a transaction that would result in a Change of Control pursuant to Section 4.4. If Astellas fails or declines to submit any such
offer within fifteen (15) Business Days following the receipt of a ROFO Notice (the “ROFO Consideration Period”), which period may be shortened or extended by mutual written agreement of the Parties, Astellas hereby consents to
Taysha soliciting other third party bids for a Change of Control transaction. 

  

	4.2	 Notice of Offer. If, during the Rett Option Period, at any time prior to delivery of a ROFO Notice,
Taysha receives an offer or proposal for a transaction from a third party that would, or could reasonably be expected to, result in a Change of Control (a “Third Party Offer”), Taysha shall immediately notify such third party of
Astellas’ rights under this Option Agreement and shall promptly, but no later than one (1) Business Day following the receipt of such offer or proposal, notify Astellas in writing of receipt of such offer or proposal and, unless
contractually prohibited, the terms thereof, including, if applicable, the price per share offered and the total value of any future milestone payments (a “Third Party Offer Notice”). If Astellas (a) fails to respond to such
Third Party Offer Notice, or (b) does not make a competing offer or proposal to Taysha for a transaction that would result in a Change of Control, in each case within fifteen (15) Business Days following the receipt of a Third Party Offer
Notice, which period may be shortened or extended by mutual written agreement of the Parties (the “Third Party Offer Consideration Period”), Astellas hereby consents to Taysha pursuing such Third Party Offer. Notwithstanding
anything contained herein, in the event that the terms of any Third Party Offer materially change at any time following the expiration of the Third Party Offer Consideration Period, Taysha shall promptly, but no later than one (1) Business Day
following the receipt of such materially amended terms, notify Astellas in writing of receipt of such materially amended Third Party Offer and provide Astellas with a subsequent fifteen (15) Business Day period to consider the amended Third
Party Offer. 

  

	4.3	 Competing Instrument. During the Rett Option Period, Taysha may not enter into (a) any letter of
intent, agreement, contract or commitment (whether or not binding) with respect to a Change of Control or (b) any agreement, contract or commitment that could impede the ability of Astellas to effect a Change of Control (a “Competing
Instrument”), unless Taysha promptly notifies Astellas, in writing, at least five (5) Business Days before entering into a Competing Instrument. Such notice shall include the terms of such Competing Instrument, unless contractually
prohibited, including, if applicable, the price per share and the total value of any future milestone payment. 

  

	4.4	 Negotiation. If, during the Rett Option Period (or the ROFO Consideration Period, if later), Astellas
submits an offer to Taysha for a transaction that would result in a Change of Control of its own accord or in response to a ROFO Notice, Astellas and Taysha will attempt to negotiate in good faith the potential terms and conditions for such a
potential transaction that would result in a Change of Control for a period of forty-five (45) days, which period may be shortened or extended by mutual written agreement of the Parties (the “COC Negotiation Period”). Until the
expiration of the COC Negotiation Period, Taysha shall not enter into, engage in, facilitate, continue or otherwise participate in any discussions or negotiations with any Persons other than Astellas regarding a Change of Control.

  
 7 

	4.5	 Definitive Agreement. The Parties hereby acknowledge and agree that (a) the Parties shall have no
obligation to enter into a definitive agreement concerning a Change of Control, and any obligations of the Parties to effect a Change of Control shall be subject to the execution of definitive agreements with respect to such Change of Control and
the receipt of all necessary approvals, including, if required, approval of the holders of the capital stock of Taysha; and (b) the Parties have the right to engage any appropriate advisors in connection with a proposed Change of Control,
including, but not limited to, seeking a customary fairness opinion. 

  

	4.6	 Definitions. For purposes of this Article 4, the following terms shall have the following meanings.

  

	 	4.6.1	 “Change of Control” means (a) a consolidation, business combination, merger or similar
transaction of Taysha or any subsidiary with or into any other corporation or other entity or Person, or any other corporate reorganization; (b) any transaction or series of related transactions in which 50% or more of Taysha’s voting
power is transferred or becomes beneficially owned by any Person or group; or (c) the sale or transfer of all or substantially all of Taysha’s assets or any asset that is material to Taysha and its subsidiaries, taken as a whole, or the
exclusive license of substantially all of Taysha’s intellectual property that is material to Taysha and its subsidiaries, taken as a whole. 

  

	 	4.6.2	 “Person” means an individual or a corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind. 

ARTICLE 5 

CONFIDENTIALITY 
  

	5.1	 Existing Confidential Disclosure Agreement. The terms and conditions of the Existing CDA, as
modified by this Section 5.1, shall govern the confidentiality and use of information disclosed by or on behalf of a Party or any of its Affiliates to the other Party or any of its Affiliates or representatives in connection with this
Agreement. The terms and conditions of the Existing CDA are hereby incorporated by reference; provided, however, that, for purposes of this Agreement: (a) the performance of a Party’s obligations or exercise of a Party’s rights
under this Agreement shall be deemed to be within the scope of the “Potential Business Arrangement” (and the evaluation thereof) under the Existing CDA (and, for clarity, each Party shall be permitted to use the Confidential Information of
the other Party as is reasonably necessary to perform its obligations or exercise its rights under this Agreement); (b) the “Disclosure Period” under the Existing CDA shall be deemed to be the Term and (without limitation to the following
clause (c)) any period thereafter during which a Party performs obligations or exercises rights under this Agreement; (c) the obligations under the Existing CDA shall apply for a period of five (5) years after the Effective Date (for
clarity, of this Agreement); and (d) Section 8 (No Representations) of the Existing CDA shall not be valid and shall be superseded by the representations, warranties and covenants set forth in this Agreement and the SPA with respect to
information disclosed on or after the Effective Date; provided that, for purposes of such representations, warranties and covenants, any information included in the GAN Data Package or the Rett Data Package shall be deemed to have been
disclosed to Astellas on or after the Effective Date. “Existing CDA” means the Confidential Disclosure Agreement entered into by and between the Parties will an Effective Date of June 21, 2022. In the event of a conflict
between the terms of the Existing CDA (as modified by this Section 5.1) and the terms of this Agreement (without incorporation of the Existing CDA), the terms of this Agreement shall govern. 

  
 8 

 ARTICLE 6 

TERM 
  

	6.1	 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and
shall continue in full force and effect until the latest of: (a) expiration of both the GAN Option Period and Rett Option Period (for clarity, whether or not the GAN Option or the Rett Option are exercised); and (b) in the event that the
GAN Option or Rett Option is exercised, the earlier of (i) expiration of the Option Negotiation Period(s) for any and all exercised Option(s), and (ii) execution of an agreement between the Parties (or their Affiliates), in accordance with
Section 3.3, with respect to any and all exercised Option(s). 

  

	6.2	 Effects of Expiration. Expiration of this Agreement shall not relieve the Parties of any obligation or
liability that, at the time of expiration, has already accrued hereunder, or which is attributable to a period prior to the effective date of such expiration. Without limitation to the foregoing, Articles 1, 4 and 5 and 8, and Sections 2.2, 3.4
and this Section 6.2 shall survive expiration of this Agreement. 

 ARTICLE 7 

REPRESENTATIONS, WARRANTIES AND COVENANTS 
  

	7.1	 Mutual Representations and Warranties. Each Party hereto represents and warrants to the other Party
that: (a) it has the full right, power and authority to enter into this Agreement and perform its obligations hereunder, (b) the execution and delivery of this Agreement has been authorized by all requisite corporate or company action of
such Party, and (c) this Agreement is and will remain a valid and binding obligation of such Party, enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors.

  

	7.2	 Additional Representations and Warranties of Taysha. 

 

	 	7.2.1	 The representations and warranties made by Taysha to Astellas pursuant to Article 2 of the SPA (and any related
definitions) are hereby incorporated by reference. 

  

	 	7.2.2	 Taysha further represents and warrants to Astellas as of the Effective Date that: 

 

	 	(a)	 neither Taysha nor any of its Affiliates has entered into any agreement with a third party, whether written or
oral, pursuant to which it assigned, transferred, licensed, conveyed, or otherwise granted any rights to develop, manufacture or commercialize any GAN Product or any Rett Product, other than with (i) a service provider contracted to perform
development or manufacturing services on behalf of Taysha or its Affiliates and (ii) in the case of the 120 GAN Product, the National Institute of Neurological Disorders and Stroke (under that certain Amended and Restated Clinical Trial
Agreement between Taysha and National Institute of Neurological Disorders and Stroke effective September 15, 2021), each of which has been disclosed to Astellas; 

 

	 	(b)	 the 120 GAN Product Diligence Package is true and correct and does not omit to state any material fact
necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading; 

  
 9 

	 	(c)	 the intellectual property, regulatory documentation, data and information Controlled by Taysha with respect to
the Exploitation of the GAN Products and the Rett Products constitute all of the intellectual property, regulatory documentation, data and information owned by or licensed (or sublicensed) or optioned to Taysha or any of its Affiliates that are
necessary or reasonably useful for such Exploitation; 

  

	 	(d)	 the products Controlled by Taysha for use in the treatment of GAN or Rett constitute all of the products owned
by or licensed (or sublicensed) or optioned to Taysha or any of its Affiliates for the treatment of GAN or Rett; and 

  

	 	(e)	 Taysha has provided to Astellas true and complete copies of all Upstream
In-Licenses. All Upstream In-Licenses are in full force and effect and, except for any modifications or amendments provided to Astellas in writing, have not been
modified or amended. Neither Taysha nor its Affiliates nor, to the best of Taysha’s knowledge, any third party licensor under any Upstream In-License, is in material breach of such Upstream In-License (including, for clarity, any diligence obligations thereunder). 

  

	7.3	 Covenants of Taysha. Taysha hereby covenants to Astellas, on behalf of itself and its Affiliates, that:

  

	 	7.3.1	 Taysha shall not, and shall cause its Affiliates not to, enter into, discuss or negotiate any agreement,
written or oral (including with respect to any assignment, transfer, license, conveyance or other encumbrance of Taysha’s or any of its Affiliate’s right, title or interest in or to any intellectual property rights that claim or cover a
GAN Product, a Rett Product or the Exploitation thereof), that would conflict with, limit or otherwise diminish the rights granted to Astellas under this Agreement (including the rights granted to Astellas under Article 3 or Article 4);

  

	 	7.3.2	 each of the GAN Data Package (as of the GAN Data Package Delivery Date) and the Rett Data Package (as of the
Rett Data Package Delivery Date) shall be true, complete and correct and shall not omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading;

  

	 	7.3.3	 Taysha (a) shall not, and shall cause its Affiliates not to, engage, in any capacity in connection with
any GAN Product or Rett Product, any third party that is debarred or subject to debarment by any regulatory authority and (b) shall promptly notify Astellas in writing if (i) it or any of its Affiliates becomes debarred or subject to
debarment by any regulatory authority or (ii) any third party engaged by Taysha or any of its Affiliates in any capacity in connection with any GAN Product or Rett Product becomes debarred or subject to debarment by any regulatory authority;

  

	 	7.3.4	 Taysha and its Affiliates shall conduct, and shall cause their respective contractors and consultants to
conduct, all development and manufacture of the GAN Products and Rett Products, including any and all non-clinical and clinical studies, in accordance with applicable law; 

  
 10 

	 	7.3.5	 during the Term, Taysha shall, and shall cause its Affiliates to, prioritize the allocation of the proceeds
from the Upfront Payment to funding the research, development, manufacture and commercialization of Rett Products in accordance with the Rett Development Plan (including the Rett Budget); and 

 

	 	7.3.6	 Taysha shall, and shall cause its Affiliates to, maintain in good standing, and not materially breach, each
Upstream In-License. Taysha shall promptly notify Astellas in writing if Taysha or any of its Affiliates sends or receives a notice of material breach under any Upstream
In-License. Taysha shall not, and shall cause its Affiliates not to, amend or modify any Upstream In-License in a manner that would adversely affect Astellas’
rights hereunder without first obtaining Astellas’ written consent. 

 ARTICLE 8 

ADDITIONAL PROVISIONS 
  

	8.1	 Disclaimer. EXCEPT AS OTHERWISE PROVIDED HEREIN (OR IN THE SPA OR THE REGISTRATION RIGHTS AGREEMENT),
NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY,
NON-INFRINGEMENT OR TITLE. 

  

	8.2	 Relationship of the Parties. Nothing in this Agreement is intended or shall be deemed, for financial,
tax, legal or other purposes, to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties. The Parties are independent contractors and at no time will either Party make commitments or incur any charges or
expenses for or on behalf of the other Party. 

  

	8.3	 Expenses. Except as otherwise provided in this Agreement, each Party shall pay its own expenses and
costs incidental to the preparation of this Agreement and to the consummation of the transactions contemplated hereby. 

  

	8.4	 Third Party Beneficiary. No party, other than Taysha or Astellas, shall be entitled to any rights
whatsoever by virtue of the relationships created by or arising under this Agreement, including, without limitation, rights as a third party beneficiary. 

  

	8.5	 Successors and Assignment. The terms and provisions hereof shall inure to the benefit of, and be binding
upon, the Parties and their respective successors and permitted assigns. Neither Party may assign or transfer this Agreement or any of its rights or obligations hereunder, by operation of law or otherwise, without the prior written consent of the
other Party; provided that (a) Astellas shall have the right to assign this Agreement to an Affiliate and (b) either Party shall have the right to assign this Agreement to a third party that acquires all or substantially all of the
business or assets of such Party to which this Agreement relates. Any assignment not in accordance with this Section 8.5 shall be void. 

  

	8.6	 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments and to
do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

  
 11 

	8.7	 Entire Agreement of the Parties; Amendments. This Agreement and its Exhibits, and the Existing CDA (as
incorporated by reference pursuant to Section 5.1), together with the SPA and the Registration Rights Agreement entered into concurrently herewith, constitute and contain the entire understanding and agreement of the Parties respecting the
subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject matter. In the event of a conflict between the terms
and conditions of the SPA or the Registration Rights Agreement and the terms and conditions of this Agreement, the terms and conditions of this Agreement shall govern with respect to the subject matter hereof. No waiver, modification or amendment of
any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party. 

 

	8.8	 Governing Law; Dispute Resolution. This Agreement shall be governed by and interpreted in accordance
with the laws of the State of Delaware, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the State of Delaware. If a dispute arises between the Parties concerning this
Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute. If the Parties are unable to resolve such dispute amicably, then, except as otherwise provided in Section 3.3, the Parties will submit to the
exclusive jurisdiction of, and venue in, the state and Federal courts located in the District of Delaware. 

  

	8.9	 Notices and Deliveries. Any notice or other communication of the Parties required or permitted to be
given or made under this Agreement will be in writing and will be deemed effective when sent in a manner that provides confirmation or acknowledgement of delivery and received at the address set forth below (or as changed by written notice pursuant
to this Section 8.9). 

  

					
	    	 	For Taysha:	  	with a copy to:
			
		 	 Contact for Notice:
 Taysha Gene
Therapies, Inc.
 3000 Pegasus Park Drive
 Suite 1430

Dallas, Texas 75247
 Attn.: General Counsel
	  	 DLA Piper LLP (US)
 Attn: Lauren Murdza

1650 Market Street, Suite 5000
 Philadelphia, PA
19103

			
		 	For Astellas:	  	with a copy to:
		 	Audentes Therapeutics, Inc.	  	Astellas US LLC
		 	 600 California Street, 17th Floor
 San
Francisco, CA 94108
	  	 1 Astellas Way
 Northbrook, IL,
60062

		 	Attn: President	  	Attention: General Counsel

  

	8.10	 Waiver. A waiver by either Party of any of the terms and conditions of this Agreement in any instance
shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and
none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 

  

	8.11	 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to
be effective and valid under law, but if any provision of this Agreement is held to be prohibited by or invalid under law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of
this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision. 

  
 12 

	8.12	 Remedies. In the event of a breach or threatened breach by either Party of any of its obligations under
this Agreement, the non-breaching Party, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, will be entitled to seek equitable relief,
including an injunction or injunctions and specific performance of its rights under this Agreement. Each Party agrees that monetary damages may not provide adequate compensation for any losses incurred by reason of a breach or threatened breach by
it of any of its obligations under this Agreement and hereby further agrees that, in the event of any action for equitable relief in respect of such a breach or threatened breach, it shall waive the defense that a remedy at law would be adequate.

  

	8.13	 Interpretation. The words “include,” “includes” and “including” shall be
deemed to be followed by the phrase “without limitation.” All references herein to Articles, Sections, and Exhibits shall be deemed references to Articles and Sections of, and Exhibits to, this Agreement unless the context shall otherwise
require. Unless otherwise indicated, “day” means “calendar day”. The term “or” is used in the inclusive sense (i.e., “and/or”). 

 

	8.14	 Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original,
and all of which together will be deemed to be one and the same instrument. An electronic, including portable document format (PDF), copy of this Agreement, including the signature pages, will be deemed an original. 

[SIGNATURE PAGE FOLLOWS] 

  
 13 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Effective
Date. 
  

									
	TAYSHA GENE THERAPIES, INC.	 		 	AUDENTES THERAPEUTICS, INC.
					
	By:	 	/s/ RA Session II	 		 	By:	 	/s/ Richard Wilson
	Name: RA Session II	 		 	Name: Richard Wilson
	Title: President and Chief Executive Officer	 		 	Title: Authorized Signatory

  
 [Signature Page to
Option Agreement] 

 Exhibit A 

Rett Development Plan & Budget 

 Exhibit B 

GAN Key Terms 

 Exhibit C 

Rett Key Terms 

 Exhibit D 

Baseball Arbitration ProceduresEX-10.2

 Exhibit 10.2 

SECURITIES PURCHASE AGREEMENT 

THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2022, by and between Taysha Gene
Therapies, Inc., a Delaware corporation (the “Company”), with its principal place of business at 3000 Pegasus Park Drive, Ste 1430, Dallas, Texas, 75247 and Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) a Delaware
corporation (the “Purchaser”) with its principal place of business at 600 California Street, 17th Floor, San Francisco, CA 94108. Capitalized terms used herein but not otherwise defined shall have the meanings given to them in
Section 1.5. 
 RECITALS 

A. On the terms and subject to the conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933,
as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated thereunder, the Company desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Company at Closing (as hereinafter
defined), that number of shares of common stock, $0.00001 par value, of the Company set forth opposite the Purchaser’s name on Schedule 1 hereto at a purchase price of $4.13 per share. 

B. The shares of Company Common Stock issued to the Purchaser pursuant to this Agreement shall be referred to in this Agreement as the
“Shares”. 
 AGREEMENT 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable
consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows: 
 ARTICLE I

 PURCHASE AND SALE 

1.1 Authorization of Sale of Shares. Subject to the terms and conditions of this Agreement and in partial consideration for the
execution of the Option Agreement entered into concurrent herewith, the Purchaser agrees to purchase from the Company that number of Shares as set forth opposite the Purchaser’s name on Schedule 1 attached hereto, at a price per Share
equal to $4.13, resulting in an aggregate purchase price of $30,009,992.46 (the “Share Purchase Price”). 
 1.2
Closing. Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, the Shares. The closing of the purchase and sale
of the Shares to the Purchaser by the Company (the “Closing”) shall occur as soon as practicable following the satisfaction or waiver of the conditions set forth in Article V but in no event more than two (2) Business
Days following the satisfaction or waiver of the conditions set forth in Article V (or at some other date and time as the Purchaser and the Company may mutually agree upon in writing) (the “Closing Date”). The Closing shall
take place at the offices of Cooley LLP, 55 Hudson Yards, New York, New York, 10001 or at such other place as the Company and the Purchaser may mutually agree upon, orally or in writing. 

  
 1 

 1.3 Payment. On the Closing Date, (a) the Purchaser shall pay to the Company the
Share Purchase Price in United States dollars and in immediately available funds, by wire transfer to the Company’s account as set forth in instructions previously delivered to the Purchaser, and (b) the Company shall irrevocably instruct
American Stock Transfer & Trust Company (the “Transfer Agent”) to deliver to such Purchaser the number of Shares set forth opposite such Purchaser’s name on Schedule 1 hereto in book-entry form in the name of
such Purchaser as set forth on the Stock Registration Questionnaire included as Exhibit A and a book-entry statement of the Transfer Agent showing such Purchaser as the registered holder of the Shares on and as of the Closing Date. 

1.4 Closing Deliverables. 

(a) Company. On or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following: 

(i) a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver the number of Shares set forth
opposite the Purchaser’s name on Schedule 1 hereto, registered in the name of the Purchaser as set forth on the Stock Registration Questionnaire included as Exhibit A; 

(ii) the Option Agreement, duly executed by the Company; 

(iii) the Registration Rights Agreement, duly executed by the Company; 

(iv) a certificate signed by an officer of the Company, in form and substance reasonably satisfactory to the Purchaser, certifying that the
conditions specified in Sections 5.1(a) and 5.1(b) are fulfilled; 
 (v) a certificate signed by the Secretary of the Company, in form and
substance reasonably satisfactory to the Purchaser, certifying as to (a) the Company’s amended and restated certificate of incorporation (the “Charter”) and the Company’s amended and restated bylaws (the
“Bylaws”); (b) the resolutions of the Company’s board of directors approving the Transaction Documents and the Transactions; and (c) a good standing certificate with respect to the Company from the Delaware Secretary of
State, dated no earlier than two (2) Business Days prior to the Closing; and 
 (vi) a duly executed cross-receipt, in form and
substance reasonably satisfactory to the parties (the “Cross-Receipt”). 
 (b) Purchaser. On or prior to the Closing
Date, the Purchaser shall deliver or cause to be delivered to the Company the following: 
 (i) a fully completed and duly executed Stock
Registration Questionnaire in the form attached hereto as Exhibit A; 
 (ii) the Option Agreement, duly executed by the Purchaser;

 (iii) the Registration Rights Agreement, duly executed by the Purchaser; 

  
 2 

 (iv) a fully completed and duly executed Accredited Investor Qualification Questionnaire in
the form attached hereto as Exhibit B; 
 (v) a fully completed and duly executed Bad Actor Questionnaire in the form attached
hereto as Exhibit C; 
 (vi) the Share Purchase Price by wire transfer to the account specified by the Company; and 

(vii) a duly executed Cross-Receipt. 

(c) Further Assurances. On or prior to the Closing Date and thereafter, the parties hereto shall execute and deliver or cause to be
executed and delivered such additional documents that take such additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the Transactions. 

1.5 Defined Terms Used in This Agreement. In addition to the terms defined elsewhere in this Agreement, the following terms have
the meanings indicated: 
 “Affiliate” means, with respect to any Person, any other Person that directly, or indirectly
through one or more intermediaries, controls or is controlled by, or is under common control with, such Person. For the purposes of this definition, “control,” when used with respect to any Person, means the possession, direct or
indirect, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise; and the terms of “affiliated,”
“controlling” and “controlled” have meanings correlative to the foregoing. 
 “Business
Day” means any day except Saturday, Sunday and any day which shall be a legal holiday or a day on which banking institutions in the state of New York or Japan generally are authorized or required by law or other government actions to close.

 “Company Common Stock” means the Company’s common stock, par value $0.00001 per share. 

“Governmental Authority” means any multi-national, federal, state, local, municipal or other government authority of any
nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal, as well as any securities exchange or securities exchange authority, including Nasdaq). 

“Investor Rights Agreement” means that certain Amended and Restated Investors’ Rights Agreement, dated as of
July 2, 2020, by and among the Company and those Persons listed on Schedule A and Schedule B thereto (and such additional Persons as may become a party thereto pursuant to Section 6.9 thereof). 

“Lien” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, mortgage, claim, easement, right-of-way, option, title retention agreement, preemptive right or other restriction. 

  
 3 

 “Material Adverse Effect” means any material adverse change or effect, or
any development that, individually or in the aggregate, could reasonably be expected to result in a material adverse change or effect, in or affecting (i) the business, properties or other assets, liabilities, general affairs, management,
financial position, stockholders’ equity, prospects or results of operations of the Company and its subsidiaries, taken as a whole, or (ii) the ability of the Company to perform its obligations under this Agreement, including the issuance
and sale of the Shares, or to consummate the Transactions. 
 “Nasdaq” means the Nasdaq Stock Market, LLC. 

“Option Agreement” means that certain Option Agreement, dated as of the Closing Date, by and between the Company and the
Purchaser, in the form of Exhibit D attached to this Agreement. 
 “Person” means an individual or a corporation,
partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind. 

“Registration Rights Agreement” means that certain Registration Rights Agreement, dated as of the Closing Date, by and
between the Company and the Purchaser, in the form of Exhibit E attached to this Agreement. 

“Transaction Documents” means this Agreement, the Option Agreement, the Registration Rights Agreement and the annexes and
exhibits attached hereto and thereto. 
 “Transactions” means the transactions contemplated by the Transaction Documents.

 ARTICLE II 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

The Company hereby represents and warrants to the Purchaser as of the date hereof and as of the Closing Date as follows. 

2.1 Organization, Good Standing and Power. The Company and each of its subsidiaries have been (i) duly organized and are validly
existing and in good standing under the laws of their respective jurisdiction of organization, with power and authority (corporate and other) to own and/or lease its properties and conduct its business as described in the reports filed by the
Company with the United States Securities and Exchange Commission (the “Commission”) pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of
the Company’s 2021 fiscal year, including, without limitation, the Company’s most recent Annual Report on Form 10-K, and (ii) duly qualified as a foreign entity for the transaction of business
and are in good standing under the laws of each other jurisdiction in which they own or lease properties or conduct any business so as to require such qualification, except, in the case of this clause (ii), where the failure to be so qualified or in
good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has no subsidiaries other than subsidiaries not required to be listed on Exhibit 21.1 to the Company’s Annual
Report on Form 10-K by Item 601 of Regulation S-K under the Exchange Act. 

  
 4 

 2.2 Authorization; Enforcement. The Company has the requisite corporate power and
authority to enter into and perform the Transaction Documents and to issue and sell the Shares to be issued by the Company in accordance with the terms hereof. The execution, delivery and performance of this Agreement by the Company and the
consummation by it of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action, and no further consent or authorization of the Company, its board of directors or stockholders is required. When
executed and delivered by the Company, this Agreement shall constitute a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy,
reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. The
Company’s board of directors adopted, by unanimous written consent, resolutions approving the transactions contemplated hereby, including the issuance of the Shares to be issued by the Company pursuant to this Agreement. 

2.3 Issuance of Shares. The Shares to be issued and sold by the Company to the Purchaser hereunder have been duly and validly
authorized and, when issued and delivered against payment therefor as provided herein, will (i) be duly and validly issued and fully paid and non-assessable; (ii) conform in all material respects to
the description of the Company Common Stock contained in the SEC Documents (as defined below); and (iii) be free and clear of any Lien or restriction on transfer, other than restrictions on transfer under any Transaction Document or applicable
state or federal securities laws; and the issuance of the Shares is not subject to any preemptive or similar rights, except as have been validly waived or complied with in connection with the offering of the Shares. 

2.4 No Conflicts; Governmental Approvals. The issuance and sale of the Shares and the compliance by the Company with this Agreement and
the consummation of the Transactions will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default (or an event which with notice or lapse of time or both would become a default) under,
(i) any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument (other than the Investor Rights Agreement) to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries
is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject (and shall not give to others any rights of termination, amendment, acceleration or cancellation of the same), (ii) the Charter, the Bylaws or
the Investor Rights Agreement, or (iii) any statute or any judgment, order, rule or regulation of any Governmental Authority having jurisdiction over the Company or any of its properties, except, in the case of clauses (i) and (iii) for
such defaults, breaches, or violations that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and no consent, approval, authorization, order, registration or qualification of or with any such
Governmental Authority is required for the issue and sale of the Shares or the consummation by the Company of the Transactions, except for filings pursuant to applicable federal or state securities or Blue Sky laws, which have been made or will be
made in a timely manner. 
 2.5 Capitalization. The authorized capital stock of the Company consists, as of October 17, 2022, of
(i) 200,000,0000 shares of Company Common Stock, of which 41,175,939 shares are issued and outstanding and (ii) 10,000,000 shares of preferred stock, $0.00001 par value per share, none of which is issued and outstanding. All of the issued shares of
capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and conform in all material respects to the description thereof contained in the SEC
Documents. 

  
 5 

 2.6 SEC Documents. The Company represents and warrants that as of the date
hereof, the Company Common Stock is registered pursuant to Section 12(b) of the Exchange Act. The Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by it with the Commission pursuant to
the reporting requirements of the Exchange Act (the “SEC Documents”). At the times of their respective filings, such reports, schedules, forms, statements and other documents of the Company (i) complied in all material respects
with the requirements of the Exchange Act and the rules and regulations promulgated thereunder and (ii) did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company understands and confirms that the Purchaser will rely on the foregoing representations in effecting transactions in securities of
the Company. No inquiries or any other investigation conducted by or on behalf of the Purchaser or its representatives will modify, amend or affect the Purchaser’s right to rely on the truth, accuracy and completeness of the SEC Documents and
the Company’s representations and warranties contained in this Agreement. 
 2.7 [Reserved]. 

2.8 Nasdaq. The Company Common Stock is currently listed on the Nasdaq. The Company is in compliance with applicable Nasdaq continued
listing requirements and has no knowledge of any facts that would reasonably lead to delisting or suspension of the Company Common Stock from Nasdaq or the termination of the registration of the Company Common Stock under the Exchange Act, and has
not received any notification that the Commission or Nasdaq is contemplating such delisting, suspension or termination. The consummation of the Transactions does not contravene the rules and regulations of Nasdaq. 

2.9 Financial Statements. As of their respective dates, the financial statements of the Company included in the SEC Documents complied
in all material respects with applicable accounting requirements and the published rules and regulations of the Commission or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance
with generally accepted accounting principles applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim
statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the consolidated financial position of the Company as of the dates thereof and the results of operations
and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). 

2.10 No Liabilities. The Company has no liabilities or obligations (accrued, absolute, contingent or otherwise), other than liabilities
or obligations (i) reflected on the most recent balance sheet of the Company included in the SEC Documents, (ii) incurred in the ordinary course of business, consistent (as to amount and nature) with past practice, since the date of the
most recent balance sheet of the Company included in the SEC Documents, (iii) incurred in connection with this Agreement, or (iv) that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  
 6 

 2.11 Accountants. Deloitte & Touche LLP, who have certified certain
financial statements of the Company, are independent public accountants as required by the Securities Act and the rules and regulations of the Commission thereunder. 

2.12 Internal Controls. The Company maintains a system of internal control over financial reporting (as such term is defined in
Rule 13a-15(f) under the Exchange Act) that (i) has been designed by the Company’s principal executive officer and principal financial officer, or under their supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and (ii) is designed to provide reasonable assurance that
(a) transactions are executed in accordance with management’s general or specific authorization, (b) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting
principles and to maintain accountability for assets, (c) access to assets is permitted only in accordance with management’s general or specific authorization; and (d) the recorded accountability for assets is compared with the
existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and the Company is not aware of any material weaknesses in its internal control over financial reporting (it being understood that this Section
shall not require the Company to comply with Section 404 of the Sarbanes Oxley Act of 2002 as of an earlier date than it would otherwise be required to so comply under applicable law). 

2.13 Disclosure Controls. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that have been designed to ensure that material information relating to the Company and its subsidiaries is made known to the Company’s principal executive officer and
principal financial officer by others within the Company; and such disclosure controls and procedures are effective in all material respects. 

2.14 Intellectual Property. Except in each case as disclosed in the SEC Documents, the Company owns or has valid, binding and
enforceable licenses or other rights to practice and use all patents and patent applications, copyrights, trademarks, trademark registrations, service marks, service mark registrations, trade names, service names and
know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) and all other technology and intellectual property rights
(1) described in the SEC Documents as being owned or licensed by it or (2) which are necessary for, or used in the conduct of, the business of the Company and its subsidiaries as currently conducted or as proposed in the SEC Documents to
be conducted (collectively, the “Company Intellectual Property”), except in the case of clause (2) where the failure to own, possess, license, have the right to use or the ability to acquire such rights would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect, and, to the Company’s knowledge, the conduct of its business has not and will not infringe or misappropriate any intellectual property rights of others; other than
as disclosed in the SEC Documents, to the knowledge of the Company, there are no rights of third parties to any of the intellectual property owned by the Company, and such intellectual property is owned by the Company free and clear of all material
Liens; other than as disclosed in the SEC Documents, the Company Intellectual Property held or licensed by the Company or its subsidiaries, 

  
 7 

 
which is material to the conduct of the business of the Company and its subsidiaries as currently conducted, is valid, enforceable and subsisting; to the Company’s knowledge, there is no
infringement by third parties of any of the Company Intellectual Property; other than as disclosed in the SEC Documents, (i) neither the Company nor its subsidiaries is obligated to pay a material royalty, grant any license, or provide any
other material consideration to any third party in connection with the Company Intellectual Property, (ii) no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, alleging that the Company or
any of its subsidiaries is infringing, misappropriating, diluting or otherwise violating any rights of others with respect to any of the Company’s products, product candidates, proposed products or processes or Company Intellectual Property,
and the Company is unaware of any facts which in the Company’s opinion could form a reasonable basis for any such action, suit, proceeding or claim, (iii) no action, suit, claim or other proceeding is pending or, to the knowledge of the
Company, is threatened, challenging the validity, enforceability, scope, registration, ownership or use of any of the Company Intellectual Property, and the Company is unaware of any facts which in the Company’s opinion could form a reasonable
basis for any such action, suit, proceeding or claim, (iv) except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, no action, suit, claim or other proceeding is pending or, to the
knowledge of the Company, is threatened, challenging the Company’s or any of its subsidiaries’ rights in or to any Company Intellectual Property, and the Company is unaware of any facts which in the Company’s opinion could form a
reasonable basis for any such action, suit, proceeding or claim, (v) neither the Company nor any of its subsidiaries has received written notice of any claim of infringement, misappropriation or conflict with any asserted rights of others with
respect to any of the Company’s or its subsidiaries’ products, product candidates, proposed products, processes or Company Intellectual Property, (vi) to the knowledge of the Company, the development, manufacture, sale, and any
currently proposed use of any of the products, product candidates, proposed products or processes of the Company referred to in the SEC Documents, in the current or proposed conduct of the business of the Company, do not currently, and will not upon
commercialization, infringe any valid patent claim or other valid intellectual property right of any third party, (vii) to the knowledge of the Company, no third party has any ownership right in or to any Company Intellectual Property in any
field of use that is exclusively licensed to the Company, other than any licensor to the Company of such Company Intellectual Property, (viii) to the knowledge of the Company, no employee, consultant or independent contractor engaged in the
development of Company Intellectual Property which is material to the business of the Company or its subsidiaries is in or has ever been in violation in any material respect of any term of any employment contract, patent disclosure agreement,
invention assignment agreement, non-competition agreement, non-solicitation agreement nondisclosure agreement or any restrictive covenant to or with a former employer or
independent contractor where the basis of such violation relates to such employee’s employment or independent contractor’s engagement with the Company or its subsidiaries or actions undertaken while employed or engaged with the Company or
its subsidiaries, (ix) the Company has taken reasonable measures to protect its confidential information and trade secrets and to maintain and safeguard the Company Intellectual Property, including the execution of commercially reasonable
nondisclosure and confidentiality agreements, (x) the Company has complied in all material respects with the terms of each agreement pursuant to which the Company Intellectual Property has been licensed to the Company, and, to the
Company’s knowledge, all such agreements are in full force and effect, (xi) the Company has the right to grant sublicenses to the Purchaser or its Affiliates under any Company Intellectual Property

  
 8 

 
in-licensed from a third party that is necessary to Exploit (as defined in the Option Agreement) the 120 GAN Product or 102 Rett Product (each, as defined
in the Option Agreement), and (xii) no Company Intellectual Property that is necessary to Exploit (as defined in the Option Agreement) the 120 GAN Product or 102 Rett Product (each, as defined in the Option Agreement) is subject to any funding
agreement with a Governmental Authority; provided, however, that the 120 GAN Product and the 102 Rett Product (each, as defined in the Option Agreement) are subject to the provisions of the Bayh-Dole Act of 1980. 

2.15 Patents. All patents and patent applications owned by or licensed to the Company or under which the Company has rights have, to
the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, there are no material defects in any of the patents or patent applications disclosed in the SEC Documents as being owned by the Company; to
the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the United States Patent and Trademark Office (the “USPTO”) and any other patent office in connection
with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO or any other patent office that were not disclosed to the USPTO or such patent office and which would preclude the grant of a patent in
connection with any such application or would reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications. 

2.16 Taxes. All material tax returns of the Company and its subsidiaries required by law to be filed have been filed and all taxes
shown as due on such returns or that otherwise have been assessed, which are due and payable, have been paid, except insofar as any failure to file a tax return or to pay a tax would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect. 
 2.17 Employee Matters. No material labor disturbance by or dispute with current or former
employees or officers of the Company exists or, to the Company’s knowledge, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of the
Company’s principal suppliers, manufacturers or contractors. The Company is not a party to any collective bargaining agreement. 
 2.18
Insurance. The Company has insurance covering its respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are
reasonable and is ordinary and customary for comparable companies in the same or similar businesses; and Company has not (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required
or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from
similar insurers as may be necessary to continue its business. 
 2.19 Anti-Corruption Laws. Neither the Company nor any subsidiary
nor any director, officer or employee nor, to the knowledge of the Company, any agent, Affiliate or other Person, while acting on behalf of the Company or any subsidiary (i) has made, offered, promised or authorized any unlawful contribution,
gift, entertainment or other unlawful expense or taken any act in furtherance thereof; (ii) has made, offered, promised or authorized any direct or indirect 

  
 9 

 
unlawful payment; (iii) has violated or is in violation of any applicable provision of the Foreign Corrupt Practices Act of 1977, as amended, the Bribery Act 2010 of the United Kingdom or
any other applicable anti-bribery or anti-corruption law (collectively, the “Anti-Corruption Laws”); or (iv) will use, directly or indirectly, the proceeds of the Transactions in furtherance of an offer, promise or
authorization of any unlawful contribution, gift, entertainment or other unlawful expense in violation of any Anti-Corruption Laws; and the Company has conducted its business in compliance with Anti-Corruption Laws and has instituted, will continue
to institute and will maintain policies and procedures reasonably designed to promote and achieve compliance with Anti-Corruption Laws and with the representations and warranties contained herein. 

2.20 Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance
with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT Act of 2001, and the rules and regulations promulgated thereunder, and the anti-money
laundering laws of the various jurisdictions in which the Company conducts business (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or Governmental Authority or any arbitrator
involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. 
 2.21
Sanctions. Neither the Company nor any of its subsidiaries nor any of their respective directors, officers, employees, or, to the knowledge of the Company, agents, Affiliates or representatives is a Person that is, or is owned or controlled
by a Person or Persons that is or are (i) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security Council, the
European Union, His Majesty’s Treasury, or other sanctions authorities, including, without limitation, designation on OFAC’s Specially Designated Nationals and Blocked Persons List or OFAC’s Foreign Sanctions Evaders List
(collectively, “Sanctions”) or (ii) located, organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with that country or territory (including, without limitation, the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic, the Crimea Region of Ukraine, Cuba, Iran, North Korea and Syria) (a “Sanctioned
Country”). Neither the Company nor any of its subsidiaries will use the proceeds of the Transactions, or lend, contribute or otherwise make available such proceeds to any Person (a) to fund or facilitate any activities or business of
or with any Sanctioned Country or any Person that, at the time of such funding or facilitation, is the subject of Sanctions or (b) in any other manner that will result in a violation of Sanctions by the Company, the Purchaser or any of their
respective Affiliates. Neither the Company nor any subsidiary has engaged in, is now engaging in or will engage in any dealings or transactions with any Sanctioned Country or with any Person that, at the time of such dealing or transaction, is or
was the subject of Sanctions. 
 2.22 Data Privacy. The Company (i) has complied and is presently in compliance, each in all
material respects, with all internal and externally published privacy policies, contractual obligations, industry standards by which the Company is legally or contractually bound, applicable laws, statutes, judgments, orders, rules and regulations
of any Governmental Authority or arbitrator and any other legal obligations, in each case, to the extent applicable and relating to the collection, use, transfer, import, export, storage, protection, disposal and disclosure by the Company of
personal, personally identifiable, or regulated data (“Data Security Obligations”, and such data, “Data”); (ii) has at all times made all disclosures to data subjects required by Data

  
 10 

 
Security Obligations, and none of such disclosures have, to the knowledge of the Company, been materially inaccurate or in material violation of any Data Security Obligation; (iii) has not
received any written notification of, or written complaint regarding, and is unaware of any other facts that, individually or in the aggregate, would reasonably indicate that the Company is in material violation of any Data Security Obligation; and
(iv) is not a party to any order or decree from a Governmental Authority that imposes any obligation or liability relating to the collection, use, transfer, import, export, storage, protection, disposal or disclosure by the Company of Data. To
the knowledge of the Company, there is no action, suit or proceeding by or before any Governmental Authority or arbitrator pending or threatened alleging non-compliance with any Data Security Obligation. 

2.23 Data Infrastructure and Controls. The Company’s information technology assets and equipment, computers, systems, networks,
hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects as required in connection with, the operation of the business of the Company
and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company has implemented commercially reasonable physical, technical and
organizational measures designed to protect the IT Systems and Data used in connection with the operation of the Company’s business. Without limiting the foregoing, the Company has used reasonable efforts to establish and maintain and implement
reasonable information technology, information security, cyber security and data protection controls, including, as applicable, oversight, access controls, encryption, technological and physical safeguards that are designed to protect against and
prevent breach, destruction, loss, unauthorized distribution, use, access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any IT Systems or Data controlled by the Company and used in connection with
the operation of the Company’s business (“Breach”). To the Company’s knowledge, there has been no material Breach or any event or condition that would reasonably be expected to result in any material Breach. 

2.24 No Material Adverse Change. Except as disclosed in the SEC Documents, since June 30, 2022, there has not been: 

(a) any change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the financial
statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, except for changes in the ordinary course of business, consistent (as to amount and nature)
with past practice, and which have not had and would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; 

(b) any declaration or payment by the Company of any dividend, or any authorization or payment by the Company of any distribution, on any of
the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company; 
 (c) any material
damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the Company; 

  
 11 

 (d) any waiver by the Company of a material right or of a material debt owed to it; 

(e) any satisfaction or discharge of a material Lien or payment of any obligation by the Company; 

(f) any change or amendment to the Charter, Bylaws or Investor Rights Agreement, or termination of or material amendment to any contract of
the Company that the Company is required to file with the Commission pursuant to Item 601(b)(10) of Regulation S-K; 

(g) any material labor difficulties or labor union organizing activities with respect to employees of the Company; 

(h) any material transaction entered into by the Company; 

(i) the loss of the services of any executive officer (as defined in Rule 405 under the Securities Act) of the Company; or 

(j) any other event or condition that has had or would, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. 
 2.25 No Undisclosed Events or Circumstances. Except as disclosed in the SEC Documents, since June 30, 2022, except
for the consummation of the transactions contemplated herein, to the Company’s knowledge, no event or circumstance has occurred or exists with respect to the Company or its businesses, properties, prospects, operations or financial condition,
which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed. 

2.26 Litigation. Except as disclosed in the SEC Documents, there are no legal or governmental proceedings pending to which the Company
or, to the Company’s knowledge, any officer or director of the Company, is a party or of which any property of the Company or, to the Company’s knowledge, any officer or director of the Company, is the subject which, if determined
adversely to the Company (or such officer or director), would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and, to the Company’s knowledge, no such proceedings are threatened or contemplated by
Governmental Authorities or others. 
 2.27 Compliance. Neither the Company nor any of its subsidiaries is (i) in violation of
their respective certificate of incorporation or by-laws (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any Governmental Authority
or body having jurisdiction over the Company, such subsidiary or any of their respective properties, or (iii) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage,
deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii) and (iii), for such violations or defaults as
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; the execution, delivery and performance of the Transaction Documents and the consummation of the Transactions will not result in (a) any such
violation or default or (b) an event which results in the creation of any Lien upon any assets of the Company 

  
 12 

 
or the suspension, revocation, forfeiture or nonrenewal of any material permit or license applicable to the Company. The Company has operated and currently is, in all material respects, in
compliance with the United States Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and all applicable rules and regulations of the United States Food and Drug Administration (the “FDA”) and other Governmental
Authorities exercising comparable authority. The Company and its subsidiaries have conducted, and to the Company’s knowledge their respective contractors and consultants have conducted, all development and manufacture of the Company’s
products and product candidates, including any non-clinical and clinical studies, in all material respects, in accordance with applicable law. 

2.28 Investment Company Act. The Company is not and, after giving effect to the Transactions, will not be an “investment
company”, as such term is defined in the Investment Company Act of 1940, as amended. 
 2.29 Private Placement. Assuming the
accuracy of the Purchaser’s representations and warranties set forth in Article III hereof, no registration under the Securities Act is required for the offer and sale of the Shares by the Company to the Purchaser hereunder. The Shares
(i) were not offered by any form of general solicitation or general advertising (as such terms are defined in Regulation D under the Securities Act) and (ii) are not being offered in a manner involving a public offering under, or in a
distribution in violation of, the Securities Act or any state securities laws. No disqualifying event described in Rule 506(d)(1)(i)-(viii) under the Securities Act (a “Disqualification Event”) is applicable to the
Company or, to the Company’s knowledge, any Company Covered Person (as defined below), except for a Disqualification Event as to which Rule 506(d)(2)(ii)-(iv) or (d)(3) under the Securities Act is applicable. The Company has complied, to the
extent applicable, with any disclosure obligations under Rule 506(e) under the Securities Act. “Company Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 under the Securities Act,
any person listed in the first paragraph of Rule 506(d)(1) under the Securities Act. 
 2.30 No Integrated Offering. The Company
shall not, directly or indirectly, sell, offer for sale or solicit offers to buy or otherwise negotiate (and has not done any of the foregoing) in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated
with the offer or sale of the Shares in a manner that would require the registration under the Securities Act of the sale of the Shares or that would be integrated with the offer or sale of the Shares for purposes of the rules and regulations of
Nasdaq such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. 

2.31 No General Solicitation. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Shares
by any form of general solicitation or general advertising (as such terms are defined in Regulation D under the Securities Act). The Company has offered the Shares for sale only to the Purchaser. 

2.32 Brokers and Finders. The Company has not employed any broker or finder in connection with the Transactions. 

  
 13 

 2.33 CFIUS. Neither the Company, its subsidiaries nor any of its Affiliates engage in
(i) the design, fabrication, development, testing, production or manufacture of one or more “critical technologies” within the meaning of Section 721 of the Defense Production Act, 50 U.S.C. § 4565, and all implementing
regulations thereof (the “DPA”); (ii) the ownership, operation, maintenance, supply, manufacture, or servicing of “covered investment critical infrastructure” within the meaning of the DPA; or (iii) the maintenance or
collection, directly or indirectly, of “sensitive personal data” of U.S. citizens within the meaning of the DPA, and, therefore, in turn, is not a “TID U.S. business” within the meaning of 31 C.F.R. § 800.248. 

2.34 Consents and Permits. The Company and its subsidiaries have made all filings, applications and submissions required by, and
possess and are operating in material compliance with, all approvals, licenses, certificates, certifications, clearances, consents, grants, exemptions, marks, notifications, orders, permits and other authorizations issued by, the appropriate
Governmental Authority (including, without limitation, the FDA, the United States Drug Enforcement Administration or any other foreign, federal, state, provincial, court or local government or regulatory authorities including self-regulatory
organizations engaged in the regulation of clinical trials, pharmaceuticals, biologics or biohazardous substances or materials) necessary for the ownership or lease of their respective properties or to conduct its businesses as described in the SEC
Documents (collectively, “Permits”), except for such Permits the failure of which to possess, obtain or make the same would not reasonably be expected to have a Material Adverse Effect; the Company and its Subsidiaries are in
compliance with the terms and conditions of all such Permits, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect; and neither the Company nor any of its subsidiaries has received any
written notice relating to the limitation, revocation, cancellation, suspension, modification or non-renewal of any such Permit, or has any reason to believe that any Permit will not be renewed. 

2.35 Clinical Studies. The preclinical studies and tests and clinical trials described in the SEC Documents were, and, if still
pending, are being conducted in all material respects in accordance with the experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable
to those being developed by the Company, including applicable regulations and guidance on Good Laboratory Practice and Good Clinical Practice; the descriptions of such studies, tests and trials, and the results thereof, contained in the SEC
Documents are accurate and complete in all material respects; to the knowledge of the Company, there are no studies, tests or trials not described in the SEC Documents the results of which reasonably call into question in any material respect the
results of the studies, tests and trials described in the SEC Documents; and the Company has not received any written notice or correspondence from the FDA or any Governmental Authority exercising comparable authority or any institutional review
board or comparable authority requiring the termination, suspension, clinical hold or material modification of any tests, studies or trials. 

  
 14 

 ARTICLE III 

REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASER 

The Purchaser, hereby represents, warrants and covenants to the Company as follows: 

3.1 Authorization and Power. Such Purchaser has the requisite power and authority to enter into and perform the Transaction Documents
and to purchase the Shares being sold to it hereunder. The execution, delivery and performance of this Agreement by such Purchaser and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary
corporate action, and no further consent or authorization of such Purchaser or its board of directors, stockholders or other governing body is required. When executed and delivered by such Purchaser, this Agreement shall constitute a valid and
binding obligation of such Purchaser, enforceable against such Purchaser in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship,
receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. 

3.2 No Conflict. The execution, delivery and performance of the Transaction Documents by such Purchaser and the consummation by such
Purchaser of the transactions contemplated hereby do not and will not (i) violate any provision of such Purchaser’s charter or organizational documents, (ii) conflict with, or constitute a default (or an event which with notice or
lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or
obligation to which such Purchaser is a party or by which such Purchaser’s properties or assets are bound, or (iii) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree
(including federal and state securities laws and regulations) applicable to such Purchaser or by which any property or asset of such Purchaser are bound or affected, except, in the case of clauses (ii) and (iii) for such conflicts, defaults or
violations that would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Purchaser to perform its obligations under this Agreement, including the purchase of the Shares, or to
consummate the Transactions. 
 3.3 Purchaser Sophistication; Accredited Investor. Such Purchaser (i) is an “accredited
investor” pursuant to Rule 501 of Regulation D under the Securities Act; (ii) is acquiring the Shares for its own account for investment only and with no present intention of distributing any of the Shares or any arrangement or
understanding with any other Persons regarding the distribution of the Shares; (iii) has not been organized, reorganized or recapitalized specifically for the purpose of investing in the Shares; (iv) will not, directly or indirectly,
offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire to take a pledge of) any of the Shares except in compliance with the Securities Act and applicable state securities laws;
(v) understands that the Shares are being offered and sold to it in reliance upon specific exemptions from the registration requirements of the Securities Act and state securities laws, and that the Company is relying upon the truth and
accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility
of such Purchaser to acquire the Shares; (vi) understands that its investment in the Shares involves a significant degree of risk, including a risk of total loss of such Purchaser’s investment (provided that such acknowledgment in no way
diminishes the representations, warranties and covenants made by the Company hereunder); and (vii) understands that no Governmental Authority has passed upon or made any recommendation or endorsement of the Shares. 

  
 15 

 3.4 Private Placement. Such Purchaser acknowledges that the Shares are being offered
in a transaction not involving a public offering within the meaning of the Securities Act and that the Shares have not been registered under the Securities Act. Such Purchaser acknowledges that the Shares may not be offered, resold, transferred,
pledged or otherwise disposed of by such Purchaser in a transaction subject to the registration requirements of the Securities Act absent an effective registration statement under the Securities Act or an applicable exemption from the registration
requirements of the Securities Act, including Rule 144 promulgated thereunder. 
 3.5 Ownership of Capital Stock. Except as
previously disclosed to the Company in writing or by email and excluding the Shares, such Purchaser and its Affiliates beneficially own no shares of capital stock of the Company as of the date hereof. 

3.6 Foreign Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue
Code of 1986, as amended), the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this Agreement, including
(i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and
(iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, sale, or transfer of the Shares. 

3.7 Stock Legends. Such Purchaser acknowledges that certificates or book-entry credits evidencing the Shares shall bear a restrictive
legend in substantially the following form (and including related stock transfer instructions and record notations): 
 THESE SECURITIES HAVE
NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS. 
 3.8 No Legal, Tax or Investment Advice. Such
Purchaser understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to such Purchaser in connection with the purchase of the Shares constitutes legal, tax or investment advice. Such Purchaser has
consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Shares. 

3.9 No General Solicitation; Pre-Existing Relationship. Such Purchaser is not purchasing the
Shares as a result of any advertisement, article, notice or other communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general
solicitation or general 

  
 16 

 
advertisement (as defined in Regulation D under the Securities Act). Such Purchaser also represents that such Purchaser was contacted regarding the sale of the Shares by the Company (or a
representative of the Company) and the Shares were offered to such Purchaser solely by direct contact between such Purchaser and the Company (or an authorized representative of the Company). Such Purchaser did not become aware of this offering of
Shares, nor were the Shares offered to such Purchaser, by any other means. 
 3.10 Purchase Entirely for Own Account. The Shares to
be received by such Purchaser hereunder will be acquired for such Purchaser’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and such Purchaser has
no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, however, to such Purchaser’s right at all times to sell or otherwise dispose of all or any
part of such Shares in compliance with applicable federal and state securities laws. Nothing contained herein shall be deemed a representation or warranty by such Purchaser to hold the Shares for any period of time. 

3.11 Experience of the Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the
economic risk of an investment in the Shares and, at the present time, is able to afford a complete loss of such investment. 
 3.12
Disclosure of Information. Such Purchaser has had an opportunity to receive all information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms
and conditions of the offering of the Shares. The Purchaser acknowledges receipt of copies of the SEC Documents (or access thereto via EDGAR). Neither such inquiries nor any other due diligence investigation conducted by such Purchaser shall modify,
limit or otherwise affect such Purchaser’s right to rely on the Company’s representations and warranties contained in this Agreement. 

3.13 [Reserved]. 
 3.14
No Rule 506 Disqualifying Activities. Neither such Purchaser nor any Person or entity with whom such Purchaser will share beneficial ownership of the Shares is subject to any of the “Bad Actor” disqualifications described in Rule
506(d)(1)(i)-(viii) under the Securities Act. 
 3.15 Brokers and Finders. Such Purchaser has not employed any broker or finder in
connection with the Transactions. 
 3.16 Disclaimer of Other Representations and Warranties. Except as expressly set forth
in Article II or in any other Transaction Document, such Purchaser acknowledges that neither the Company nor any other Person has made or is making any representation or warranty of any kind, express or implied, at
law or in equity, including with respect to it or any of its subsidiaries or any of their respective businesses, assets, liabilities, condition (financial or otherwise), prospects or operations, or otherwise, and any such other representations and
warranties are hereby expressly disclaimed by the Company. 

  
 17 

 ARTICLE IV 

COVENANTS OF THE PARTIES 

4.1 Lockup. 
 (a)
Agreement to Lock-Up. The Purchaser hereby agrees that it will not, without the prior written consent of the Company during the period commencing on the Closing Date and ending on the date that
is one hundred and eighty (180) days after the Closing Date (the “Lock-Up Period”) (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Company Common Stock; or (ii) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of any shares of Company Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Company Common Stock or other
securities, in cash or otherwise. Notwithstanding the foregoing, the Purchaser or its Permitted Transferees may transfer shares of Company Common Stock during the Lock-Up Period (i) to (a) such
Purchaser’s Affiliates and its and their respective officers or directors, (b) any immediate family members of such officers or directors, or (c) any direct or indirect partners, members or equity holders of Purchaser or any related
investment funds or vehicles controlled or managed by such Persons or entities or their respective Affiliates, (ii) to the Company; or (iii) in connection with a liquidation, merger, stock exchange, reorganization, tender offer or other
similar transaction which results in all of the Company’s stockholders having the right to exchange their shares of Company Common Stock for cash, securities or other property subsequent to the Closing Date; provided, however,
that in the case of clauses (i)(a) to (i)(c), it shall be a condition to the transfer that the Permitted Transferee execute an agreement stating that the Permitted Transferee is receiving and holding such capital stock subject to this
Section 4.1 and there shall be no further transfer of such capital stock except in accordance with this Section 4.1, and provided further that any such transfer shall not involve a disposition for value. The term “Permitted
Transferees” means, prior to the expiration of the Lock-Up Period, any Person or entity to whom such Purchaser is permitted to transfer such shares of Company Common Stock prior to the expiration of
the Lock-Up Period pursuant to this Section 4.1(a). 
 (b) Stop Transfer Instructions.
In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the shares of Company Common Stock of such Purchaser (and transferees and assignees thereof) until the end of the Lock-Up Period. 
 4.2 Board Observer. As of the Closing Date, the Purchaser shall have the right
(but not the obligation) to designate one (1) individual (the “Board Observer”). The Board Observer may, at his or her option, attend any or all meetings of the Company’s board of directors (or any portion thereof) in a
nonvoting observer capacity and, in this respect, the Company shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such
directors, except that the Board Observer may be excluded from access to any material, meeting or portion thereof if the Company reasonably believes, upon written advice of counsel, that such exclusion is reasonably necessary to preserve the
attorney-client privilege between the Company and its counsel. The right to a Board Observer will terminate upon the earliest to occur of a Change of Control (as defined 

  
 18 

 
below) of the Company or the date on which the Purchaser ceases to hold any shares of the Company Common Stock. As used herein, “Change of Control” means (i) a consolidation
or merger of the Company with or into any other Person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of the Company immediately prior to such consolidation,
merger or reorganization continue to represent a majority of the voting power of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related transactions to which the Company is
a party in which in excess of 50% of the Company’s voting power is transferred; or (iii) the sale or transfer of all or substantially all of the Company’s assets, or the exclusive license of all or substantially all of the material
Company Intellectual Property; provided that a Change of Control shall not include any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or any successor, indebtedness
of the Company is cancelled or converted or a combination thereof. 
 4.3 [Reserved]. 

4.4 Indemnification. 

(a) The Company agrees to indemnify and hold harmless the Purchaser, its Affiliates and its and their respective directors, officers,
stockholders, members, partners, employees and agents (and any other persons with a functionally equivalent role of a person holding such titles notwithstanding a lack of such title or any other title), each person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other persons with a functionally equivalent role of a
person holding such titles notwithstanding a lack of such title or any other title) of such controlling person (collectively, the “Purchaser Indemnitees”), from and against all losses, liabilities, claims, damages, costs, fees and
expenses whatsoever (including, but not limited to, any and all expenses incurred in investigating, preparing or defending against any litigation commenced or threatened) based upon or arising out of the Company’s breach of any representation,
warranty or covenant contained herein; provided, however, that the Company will not be liable in any such case to the extent and only to the extent that any such loss, liability, claim, damage, cost, fee or expense arises out of or is based upon the
inaccuracy of any representations made by the Purchaser in this Agreement, or the failure of the Purchaser to comply with the covenants and agreements contained herein. 

(b) Promptly after receipt by an indemnified party under this Section 4.4 of notice of the commencement of any indemnifiable action, such
indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section 4.4, notify the indemnifying party in writing of the commencement thereof; but the omission so to notify the indemnifying
party will not relieve it from any liability which it may have to any indemnified party otherwise than under this Section 4.4 except to the extent the indemnified party is actually prejudiced by such omission. In case any such indemnifiable
action is brought against any indemnified party, the indemnifying party will be entitled to participate therein, and to the extent that it may elect by written notice delivered to the indemnified party promptly after receiving the aforesaid notice
from such indemnified party, to assume the defense thereof, with counsel satisfactory to such indemnified party; provided, however, if the defendants in any such indemnifiable action include both the indemnified party and the indemnifying party and
either (i) 

  
 19 

 
the indemnifying party or parties and the indemnified party or parties mutually agree or (ii) representation of both the indemnifying party or parties and the indemnified party or parties by
the same counsel is inappropriate under applicable standards of professional conduct due to actual or potential differing interests between them, the indemnified party or parties shall have the right to select separate counsel to assume such legal
defenses and to otherwise participate in the defense of such indemnifiable action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of its election so to assume the defense
of such indemnifiable action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section 4.4 for any reasonable legal or other expenses subsequently incurred by such
indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed counsel in connection with the assumption of legal defenses in accordance with the proviso to the next preceding sentence (it being
understood, however, that the indemnifying party shall not be liable for the expenses of more than one separate counsel in such circumstance), (ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to
represent the indemnified party within a reasonable time after notice of commencement of the indemnifiable action or (iii) the indemnifying party has authorized the employment of counsel for the indemnified party at the expense of the
indemnifying party. No indemnifying party shall (i) without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened indemnifiable action in
respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such indemnifiable action) unless such settlement, compromise or consent requires only the payment of
money damages, does not subject the indemnified party to any continuing obligation or require any admission of criminal or civil responsibility or fault, and includes an unconditional release of each indemnified party from all liability arising out
of such indemnifiable action, or (ii) be liable for any settlement of any such indemnifiable action effected without its written consent, but if settled with its written consent or if there be a final judgment of the plaintiff in any such
indemnifiable action, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or liability by reason of such settlement or judgment. 

ARTICLE V 
 CONDITIONS TO
CLOSING 
 5.1 Conditions Precedent to the Obligations of the Purchaser. The obligation of the Purchaser to acquire the Shares at
the Closing is subject to the satisfaction or waiver by the Purchaser, at or before the Closing, of each of the following conditions: 
 (a)
Representations and Warranties. The representations and warranties of the Company contained in Article II shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date, except to the extent any
such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date. 

(b) Performance. The Company shall have performed and complied, in all material respects, with all covenants, agreements, obligations
and conditions contained in this Agreement that are required to be performed or complied with by the Company on or before the Closing, including, without limitation, the delivery by the Company of the items contemplated by Section 1.4(a). 

  
 20 

 (c) No Injunction. No statute, rule, regulation, executive order, decree, ruling or
injunction shall have been enacted, entered, promulgated or endorsed by any Governmental Authority or arbitrator of competent jurisdiction that prohibits the consummation of any of the Transactions. 

(d) No Nasdaq Objection. Nasdaq shall have raised no objection to the consummation of the Transactions in the absence of stockholder
approval of such transactions. 
 (e) Listing of Additional Shares. The Company shall have submitted a Listing of Additional Shares
Notification with the Nasdaq covering all of the Shares. 
 (f) Option Agreement. The Company shall have executed and delivered the
Option Agreement, and the Option Agreement shall be in full force and effect 
 (g) Registration Rights Agreement. The Company shall
have executed and delivered the Registration Rights Agreement, and the Registration Rights Agreement shall be in full force and effect. 

(h) Wire Instructions. The Company shall have delivered wire transfer instructions with respect to the Share Purchase Price to the
Purchaser at least ten (10) Business Days prior to the Closing. 
 5.2 Conditions Precedent to the Obligations of the
Company. The obligation of the Company to issue the Shares at the Closing is subject to the satisfaction or waiver by the Company, at or before the Closing, of each of the following conditions: 

(a) Representations and Warranties. The representations and warranties of the Purchaser contained in Article III shall be true
and correct in all respects as of the Closing (unless as of a specific date therein in which case they shall be accurate as of such date). 

(b) Performance. The Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and
conditions required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the Closing, including, without limitation, the delivery by such Purchaser of the items contemplated by
Section 1.4(b). 
 (c) No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have
been enacted, entered, promulgated or endorsed by any Governmental Authority or arbitrator of competent jurisdiction that prohibits the consummation of any of the Transactions. 

(d) No Nasdaq Objection. Nasdaq shall have raised no objection to the consummation of the Transactions in the absence of stockholder
approval of such Transactions. 

  
 21 

 ARTICLE VI 

MISCELLANEOUS 
 6.1
Survival. Unless otherwise set forth in this Agreement, the representations, warranties, covenants and agreements (including those relating to the Board Observer and any obligation of indemnification) of the Company and the Purchaser
contained in or made pursuant to this Agreement shall survive the Closing and the delivery of the Shares. 
 6.2 No
Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or commission in connection with the Transactions. The Company agrees to indemnify and to hold harmless the Purchaser from
any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of such Transactions (and the costs and expenses of defending against such liability or asserted liability) for which the Company or
any of its officers, employees or representatives is responsible. The Purchaser agrees to indemnify and hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out
of such transactions (and the costs and expenses of defending against such liability or asserted liability) for which such Purchaser or any of its officers, employees or representatives is responsible. 

6.3 Fees and Expenses. Each party shall pay the fees and expenses of its advisors, counsel, accountants and other experts, if any, and
all other expenses, incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. 

6.4 Entire Agreement. The Transaction Documents, together with the Exhibits and Schedules thereto, contain the entire
understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits
and schedules; provided, however, that any confidentiality agreements previously entered into between the Company and the Purchaser shall remain in full force and effect. 

6.5 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this Section (if any)
prior to 4:00 p.m. (New York City time) on a Business Day, (b) the next Business Day after the date of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this
Section (if any) on a day that is not a Business Day or later than 4:00 p.m. (New York City time) on any Business Day, (c) the Business Day following the date of deposit with a nationally recognized overnight courier service, or (d) upon
actual receipt by the party to whom such notice is required to be given. The addresses, facsimile numbers and email addresses for such notices and communications are those set forth below, or such other address or facsimile number as may be
designated in writing hereafter, in the same manner, by any such Person: 
  

			
	If to the Company:	  	Taysha Gene Therapies, Inc.
	 	  	3000 Pegasus Park Drive, Suite 1430
	 	  	Dallas, Texas 75247
	 	  	 Attention: Chief Financial Officer
 Email:
KAlam@tayshagtx.com

  
 22 

			
	 with copies (which copies
 shall not constitute
notice
 to the Company) to:
	  	 Cooley LLP
 55 Hudson Yards

New York, New York 10001
 Attention: Divakar Gupta

Email: dgupta@cooley.com

		
	If to the Purchaser:	  	To their address as set forth on Schedule 1 hereto.

 6.6 Amendments; Waivers. This Agreement and any term hereof may be amended, terminated or waived only
with the written consent of the Company and the Purchaser. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent
default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. 

6.7 Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 

6.8 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Purchaser. The Purchaser may assign its rights under this Agreement only to a Person to whom such Purchaser
assigns or transfers all Shares held by such Purchaser; provided, that (i) as a condition of such transfer, such transferee agrees in writing to be bound by all of the terms and conditions of this Agreement as if it were Purchaser
hereunder and (ii) such transfer shall have been made in accordance with the applicable requirements of this Agreement. 
 6.9
Persons Entitled to Benefit of Agreement. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns and is not for the benefit of, nor may any provision hereof be
enforced by, any other Person, except that Section 4.4 hereof shall be for the express benefit of the indemnified persons identified therein. 

6.10 Governing Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the internal laws of
the State of Delaware without regard to the choice of law principles thereof. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the Delaware Chancery Court (or, if the Delaware Chancery Court shall be unavailable,
then any federal court of the United States of America sitting in the State of Delaware) for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of
process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably

  
 23 

 
consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of
venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 

6.11 Counterparts; Execution. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.12 Severability. If any provision hereof should be held invalid, illegal or unenforceable in any respect, then, to the fullest extent
permitted by law, (a) all other provisions hereof shall remain in full force and effect and shall be liberally construed in order to carry out the intentions of the parties as nearly as may be possible and (b) the parties shall use their
best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of such provision(s) in this Agreement. 

6.13 Adjustments in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares
of Company Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Company Common Stock), combination or other similar recapitalization or event occurring after the
date hereof, each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account for such event. 

[SIGNATURE PAGES TO FOLLOW] 

  
 24 

 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement
to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	COMPANY:
	
	TAYSHA GENE THERAPIES, INC.
		
	By:	 	/s/ RA Session II
		 	RA Session II
		 	President and Chief Executive Officer

  
 [Signature Page to
Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement
to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	PURCHASER:
	
	AUDENTES THERAPEUTICS, INC.
		
	By:	 	/s/ Richard Wilson
	Name:	 	Richard Wilson
	Title:	 	Authorized Signatory

  
 [Signature Page to
Securities Purchase Agreement] 

 SCHEDULE 1 

SCHEDULE OF PURCHASERS 

 Exhibit A 

STOCK REGISTRATION QUESTIONNAIRE 

 Exhibit B 

ACCREDITED INVESTOR QUALIFICATION QUESTIONNAIRE 

 Exhibit C 

“BAD ACTOR” QUESTIONNAIRE FORMS 

 Exhibit D 

OPTION AGREEMENT 

 Exhibit E 

REGISTRATION RIGHTS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]